Wnt-C59
Based on 37 publication(s) in Google Scholar
Wnt-C59 (C59) is a highly potent and oral porcupine (PORCN) inhibitor with an IC50 of 74 pM.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.88%
- CAS No.: 1243243-89-1
- Formule: C25H21N3O
- Masse moléculaire:379.45
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
-
Immunology/Inflammation Compound Library
HY-L007
-
Stem Cell Signaling Compound Library
HY-L017
-
Wnt/Hedgehog/Notch Compound Library
HY-L020
-
Anti-Cancer Compound Library
HY-L025
-
Anti-Aging Compound Library
HY-L034
-
Differentiation Inducing Compound Library
HY-L038
-
Anti-Cardiovascular Disease Compound Library
HY-L046
-
Cytoskeleton Compound Library
HY-L060
-
Neuroprotective Compound Library
HY-L070
-
Anti-Breast Cancer Compound Library
HY-L074
-
Anti-Liver Cancer Compound Library
HY-L101
-
Anti-Colorectal Cancer Compound Library
HY-L103
-
Human Metabolite Library
HY-L123
-
Anti-Prostate Cancer Compound Library
HY-L124
-
Anti-Pulmonary Fibrosis Compound Library
HY-L125
-
Cancer Stem Cells Compound Library
HY-L135
-
Heterocyclic Compound Library
HY-L138
-
Antihypertensive Compound Library
HY-L145
-
Extracellular Vesicles (EVs) Compound Library
HY-L168
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
Anti-Aging Compound Library Mini
HY-L034M
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Anti-Gastric Cancer Compound Library
HY-L184
-
Anti-Fibrosis Compound Library
HY-L185
-
High-Throughput Bioactive Compound Library
HY-L205
-
Anti-Rheumatic Arthritis Compound Library
HY-L210
-
Mass Spectrometry Human Metabolite Library
HY-L215
Publications Citing Use of MedChemExpress (MCE) Wnt-C59
More- Exp Mol Med. 2026 Feb;58(1):227-242. [Abstract]
- Gut Microbes. 2023 Jan-Dec;15(1):2233149. [Abstract]
- J Exp Clin Cancer Res. 2020 Jan 28;39(1):22. [Abstract]
- Adv Sci (Weinh). 2025 Sep 3:e05270. [Abstract]
- Adv Sci (Weinh). 2025 Aug 22:e08451. [Abstract]
- Acta Pharmacol Sin. 2026 Jan 16. [Abstract]
- Acta Pharmacol Sin. 2026 Jan 7. [Abstract]
- Cell Chem Biol. 2025 Oct 22:S2451-9456(25)00306-X. [Abstract]
- Int J Mol Med. 2018 Aug;42(2):1008-1017. [Abstract]
- Br J Cancer. 2025 Dec 13. [Abstract]
- Stem Cell Res Ther. 2024 Feb 5;15(1):31. [Abstract]
- Cell Rep. 2023 Oct 30;42(11):113340. [Abstract]
- Front Immunol. 2021 Mar 15:12:619209. [Abstract]
- JCI Insight. 2024 Dec 5:e181857. [Abstract]
- Mol Ther Nucleic Acids. 2021 May 29:26:22-33. [Abstract]
- EMBO Rep. 2023 Apr 5;24(4):e54895. [Abstract]
- Int J Mol Sci. 2024 Jan 24;25(3):1427. [Abstract]
- Int J Mol Sci. 2021 Jun 10;22(12):6249. [Abstract]
- Stem Cells. 2019 Apr;37(4):489-503. [Abstract]
- Oncol Res. 2023 May 24;31(3):317-331. [Abstract]
- iScience. 2025 Jun 26;28(8):113013. [Abstract]
- J Med Genet. 2022 Dec;59(12):1139-1149. [Abstract]
- Theriogenology. 2020 May;148:8-17. [Abstract]
- Theriogenology. 2019 Oct 15:138:84-93. [Abstract]
- Discov Oncol. 2023 Jul 25;14(1):137. [Abstract]
- Korean J Physiol Pharmacol. 2021 Jul 1;25(4):307-319. [Abstract]
- Cell Physiol Biochem. 2017;44(3):1251-1262. [Abstract]
- Exp Ther Med. 2018 Oct;16(4):2835-2842. [Abstract]
- bioRxiv. 2026 May 19:2026.05.16.724973. [Abstract]
- Northwestern University. 2026.
- Res Sq. 2025 Nov 10.
- bioRxiv. 2025 January 20.
- bioRxiv. 2024 November 15.
- medRxiv. 2023 Dec 20.
- Patent. US20220370428A1.
- Research Square Print. September 14th, 2022.
- ACS Comb Sci. 2019 Dec 9;21(12):805-816. [Abstract]
Customer Validation & Images
-
2D/3D Cell Culture and Differentiation
-
Histological Imaging/Staining
-
Histological Imaging/Staining
-
WB
-
RT-PCR
Activité biologique
IC50: 74 pM (PORCN)[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HT-1080 | IC50 |
74 pM
Compound: C59
|
Inhibition of porcupine activity (unknown origin) expressed in human HT1080 cells assessed as suppression of Wnt3A-mediated super top flash activity by STF luciferase assay
Inhibition of porcupine activity (unknown origin) expressed in human HT1080 cells assessed as suppression of Wnt3A-mediated super top flash activity by STF luciferase assay
|
[PMID: 26522946] |
Wnt-C59 (C59) inhibits PORCN activity in vitro at nanomolar concentrations, as assessed by inhibition of Wnt palmitoylation, Wnt interaction with the carrier protein Wntless/WLS, Wnt secretion, and Wnt activation of β-catenin reporter activity. Wnt-C59 inhibits WNT3A-mediated activation of a multimerized TCF-binding site driving luciferase with an IC50 of 74 pM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Wnt-C59 has the potential to eradicate cancer stem cells in human tumors. Wnt-C59 inhibits stemness properties of NPC cells in a dosage-dependent manner by arresting sphere formation in both HNE1 and SUNE1 cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 1243243-89-1
-
Appearance Solid
-
Masse moléculaire 379.45
-
Formule C25H21N3O
-
Color White to yellow
-
SMILES
O=C(NC1=CC=C(C2=CC=CN=C2)C=C1)CC3=CC=C(C4=CC(C)=NC=C4)C=C3
-
Synonyms
C59
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (37)
-
Journal Impact Factor
-
Most Recent
-
Exp Mol Med
Switching off CK2-mediated activation of survivin offers new therapeutic opportunities in neuroblastoma. [Abstract]2026 Feb;58(1):227-242. PMID: 41571889 -
Gut Microbes
Fucose promotes intestinal stem cell-mediated intestinal epithelial development through promoting Akkermansia-related propanoate metabolism. [Abstract]2023 Jan-Dec;15(1):2233149. PMID: 37424378
Wnt-C59 purchased from MedChemExpress. Usage Cited in: Gut Microbes. 2023 Jan-Dec;15(1):2233149. [Abstract]
Images of organoids that were treated with ileal contents from control and fucose-treated mice when there were Wnt signaling inhibitor Wnt-c59 (100 nM).
Wnt-C59 purchased from MedChemExpress. Usage Cited in: Gut Microbes. 2023 Jan-Dec;15(1):2233149. [Abstract]
Lgr5-EGFP staining of organoids that were treated with ileal contents from control and fucose-treated mice when there were Wnt signaling inhibitor Wnt-c59 (100 nM).
Wnt-C59 purchased from MedChemExpress. Usage Cited in: Gut Microbes. 2023 Jan-Dec;15(1):2233149. [Abstract]
EdU staining of organoids that were treated with ileal contents from control and fucose-treated mice when there were Wnt signaling inhibitor Wnt-c59 (100 nM).
-
J Exp Clin Cancer Res
Hedgehog signaling promotes sorafenib resistance in hepatocellular carcinoma patient-derived organoids. [Abstract]2020 Jan 28;39(1):22. PMID: 31992334
Wnt-C59 purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2020 Jan 28;39(1):22. [Abstract]
4 HCC PDOs were treated with a Notch signaling inhibitor (YO-01027), Wnt signaling inhibitor (Wnt-C59, 0-20 μM), Hippo signaling inhibitor (verteporfin), or Hedgehog signaling inhibitor (GANT61) for 6 days and cell viability was recorded.
-
Adv Sci (Weinh)
Preservation of ALYREF Phase Separation Mitigates Doxorubicin-Induced Cardiomyocyte DNA Damage and Cardiotoxicity. [Abstract]2025 Sep 3:e05270. PMID: 40899520 -
Adv Sci (Weinh)
2025 Aug 22:e08451. PMID: 40847444 -
Acta Pharmacol Sin
PLN-L31A/I40A for the treatment of inherited heart disease caused by PLN-R14del mutations. [Abstract]2026 Jan 16. PMID: 41545752 -
Acta Pharmacol Sin
Inhibiting L-type calcium channel promotes cardiomyocyte proliferation through activating the canonical Wnt signaling pathway. [Abstract]2026 Jan 7. PMID: 41501415 -
Cell Chem Biol
STT3A is essential for Wnt signaling and represents a target for cancers driven by RNF43 deficiency. [Abstract]2025 Oct 22:S2451-9456(25)00306-X. PMID: 41130209 -
Int J Mol Med
2018 Aug;42(2):1008-1017. PMID: 29750292 -
Br J Cancer
Fibroblast growth factor signals drive the metastatic behavior in small cell lung cancer. [Abstract]2025 Dec 13. PMID: 41390896 -
Stem Cell Res Ther
HAND factors regulate cardiac lineage commitment and differentiation from human pluripotent stem cells. [Abstract]2024 Feb 5;15(1):31. PMID: 38317221 -
Cell Rep
2023 Oct 30;42(11):113340. PMID: 37906593 -
Front Immunol
Wnt Inhibition Sensitizes PD-L1 Blockade Therapy by Overcoming Bone Marrow-Derived Myofibroblasts-Mediated Immune Resistance in Tumors. [Abstract]2021 Mar 15:12:619209. PMID: 33790893 -
JCI Insight
WNT signaling contributes to the extrahepatic bile duct proliferative response to obstruction in mice. [Abstract]2024 Dec 5:e181857. PMID: 39636699 -
Mol Ther Nucleic Acids
ALKBH5-mediated m6A mRNA methylation governs human embryonic stem cell cardiac commitment. [Abstract]2021 May 29:26:22-33. PMID: 34513291 -
EMBO Rep
Noncanonical Wnt signaling promotes colon tumor growth, chemoresistance and tumor fibroblast activation. [Abstract]2023 Apr 5;24(4):e54895. PMID: 36704936
Wnt-C59 purchased from MedChemExpress. Usage Cited in: EMBO Rep. 2023 Apr 5;24(4):e54895. [Abstract]
LAKTP murine tumor (MTO) cells were seeded in the indicated culture conditions and supplemented with LGK (10 μM) or WntC59 (100 nM). Total protein extracts were obtained and analyzed after 16 h of treatment.
Wnt-C59 purchased from MedChemExpress. Usage Cited in: EMBO Rep. 2023 Apr 5;24(4):e54895. [Abstract]
LAKTP murine tumor (MTO) cells were seeded in the indicated culture conditions and supplemented with LGK (10 μM) or WntC59 (100 nM). Total RNA extracts were obtained and analyzed after 16 h of treatment.
Wnt-C59 purchased from MedChemExpress. Usage Cited in: EMBO Rep. 2023 Apr 5;24(4):e54895. [Abstract]
Cell number was analyzed by CellTiter‐Go assay in MTO cells supplemented with WntC59 (100 nM) every 3 days (mean ± SD of three biological replicates).
-
Int J Mol Sci
Unveiling the Antiviral Properties of Panduratin A through SARS-CoV-2 Infection Modeling in Cardiomyocytes. [Abstract]2024 Jan 24;25(3):1427. PMID: 38338708 -
Int J Mol Sci
Wnt-Signaling Inhibitor Wnt-C59 Suppresses the Cytokine Upregulation in Multiple Organs of Lipopolysaccharide-Induced Endotoxemic Mice via Reducing the Interaction between β-Catenin and NF-κB. [Abstract]2021 Jun 10;22(12):6249. PMID: 34200709 -
Stem Cells
Iron Homeostasis Determines Fate of Human Pluripotent Stem Cells Via Glycerophospholipids-Epigenetic Circuit. [Abstract]2019 Apr;37(4):489-503. PMID: 30599084 -
Oncol Res
Calcyclin-binding protein contributes to cholangiocarcinoma progression by inhibiting ubiquitination of MCM2. [Abstract]2023 May 24;31(3):317-331. PMID: 37305391 -
iScience
Cardiac fibrosis inhibitor CTPR390 prevents structural and morphological changes in human engineered cardiac connective tissue. [Abstract]2025 Jun 26;28(8):113013. PMID: 40686602 -
J Med Genet
Association between SCN5A R225Q variant and dilated cardiomyopathy: potential role of intracellular pH and WNT/β-catenin pathway. [Abstract]2022 Dec;59(12):1139-1149. PMID: 35701104 -
Theriogenology
3, 3', 5-Triiodo-L-thyronine affects polarity proteins of bovine Sertoli cells via WT1/non-canonical Wnt signaling pathway. [Abstract]2020 May;148:8-17. PMID: 32126395 -
Theriogenology
Influence of Wilms' tumor suppressor gene WT1 on bovine Sertoli cells polarity and tight junctions via non-canonical WNT signaling pathway. [Abstract]2019 Oct 15:138:84-93. PMID: 31302435 -
Discov Oncol
Propofol inhibits colon cancer cell stemness and epithelial-mesenchymal transition by regulating SIRT1, Wnt/β-catenin and PI3K/AKT/mTOR signaling pathways. [Abstract]2023 Jul 25;14(1):137. PMID: 37490168 -
Korean J Physiol Pharmacol
Wnt-C59 inhibits proinflammatory cytokine expression by reducing the interaction between β-catenin and NF-κB in LPS-stimulated epithelial and macrophage cells. [Abstract]2021 Jul 1;25(4):307-319. PMID: 34193644 -
Cell Physiol Biochem
VEGF-A/Neuropilin 1 Pathway Confers Cancer Stemness via Activating Wnt/β-Catenin Axis in Breast Cancer Cells. [Abstract]2017;44(3):1251-1262. PMID: 29179185
Wnt-C59 purchased from MedChemExpress. Usage Cited in: Cell Physiol Biochem. 2017;44(3):1251-1262. [Abstract]
The protein levels of Wnt3a and β-catenin are examined in MCF-7 spheres and MDA-MB-231 spheres with Wnt-C59 treatment or not via western blot analysis.
-
Exp Ther Med
MicroRNA-139-5p elevates skeletal myogenic differentiation of human adult dental pulp stem cells through Wnt/β-catenin signaling pathway. [Abstract]2018 Oct;16(4):2835-2842. PMID: 30233663 -
bioRxiv
Elongin B orchestrates chromatin and transcriptional programs in H3K27M-mutant diffuse midline glioma. [Abstract]2026 May 19:2026.05.16.724973. PMID: 42239282 -
-
-
-
-
-
-
-
ACS Comb Sci
Benzimidazolyl-pyrazolo[3,4- b]pyridinones, Selective Inhibitors of MOLT-4 Leukemia Cell Growth and Sea Urchin Embryo Spiculogenesis: Target Quest. [Abstract]2019 Dec 9;21(12):805-816. PMID: 31689077
Solvant et solubilité
DMSO : 50 mg/mL (131.77 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.59 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.59 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocole
1×104 HK1, CNE1, HNE1 and SUNE1 cells are seeded in 24-well plates, and Wnt-C59 (5 μM, 10 μM, and 20 μM) is added the next day. Cell confluence is determined by microscopy at 24, 48, 72, and 96 hours after seeding of cells. The IC50 is determined by MTT assay[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Mice[1]
Female nude mice orthotopically transplanted with independent MMTV-WNT1 tumors are treated with vehicle or Wnt-C59 10 mg/kg once daily for 17 days. Tumor volumes are measured on alternate days[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Pureté et documentation
-
Fiche technique (273 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Proffitt KD, et al. Pharmacological inhibition of the Wnt acyltransferase PORCN prevents growth of WNT-driven mammary cancer. Cancer Res. 2013 Jan 15;73(2):502-7. [Content Brief]
[2]. Cheng Y, et al. Wnt-C59 arrests stemness and suppresses growth of nasopharyngeal carcinoma in mice by inhibiting the Wnt pathway in the tumor microenvironment. Oncotarget. 2015 Jun 10;6(16):14428-39. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.6354 mL | 13.1770 mL | 26.3539 mL | 65.8848 mL |
| 5 mM | 0.5271 mL | 2.6354 mL | 5.2708 mL | 13.1770 mL | |
| 10 mM | 0.2635 mL | 1.3177 mL | 2.6354 mL | 6.5885 mL | |
| 15 mM | 0.1757 mL | 0.8785 mL | 1.7569 mL | 4.3923 mL | |
| 20 mM | 0.1318 mL | 0.6588 mL | 1.3177 mL | 3.2942 mL | |
| 25 mM | 0.1054 mL | 0.5271 mL | 1.0542 mL | 2.6354 mL | |
| 30 mM | 0.0878 mL | 0.4392 mL | 0.8785 mL | 2.1962 mL | |
| 40 mM | 0.0659 mL | 0.3294 mL | 0.6588 mL | 1.6471 mL | |
| 50 mM | 0.0527 mL | 0.2635 mL | 0.5271 mL | 1.3177 mL | |
| 60 mM | 0.0439 mL | 0.2196 mL | 0.4392 mL | 1.0981 mL | |
| 80 mM | 0.0329 mL | 0.1647 mL | 0.3294 mL | 0.8236 mL | |
| 100 mM | 0.0264 mL | 0.1318 mL | 0.2635 mL | 0.6588 mL |
Wnt-C59 Related Classifications
HY-15659 Related Classifications
Powered by Bioz